Literature DB >> 11467622

Hepatic Encephalopathy.

A T Blei1, J Córdoba.   

Abstract

1. Acute Encephalopathy in Cirrhosis A. GENERAL MEASURES. Tracheal intubation in patients with deep encephalopathy should be considered. A nasogastric tube is placed for patients in deep encephalopathy. Avoid sedatives whenever possible. Correction of the precipitating factor is the most important measure. B. SPECIFIC MEASURES i. Nutrition. In case of deep encephalopathy, oral intake is withheld for 24-48 h and i.v. glucose is provided until improvement. Enteral nutrition can be started if the patient appears unable to eat after this period. Protein intake begins at a dose of 0.5 g/kg/day, with progressive increase to 1-1.5 g/kg/day. ii. Lactulose is administered via enema or nasogastric tube in deep encephalopathy. The oral route is optimized by dosing every hour until stool evacuation appears. Lactulose can be replaced by oral neomycin. iii. Flumazenil may be used in selected cases of suspected benzodiazepine use. 2. Chronic Encephalopathy in Cirrhosis i. Avoidance and prevention of precipitating factors, including the institution of prophylactic measures. ii. Nutrition. Improve protein intake by feeding dairy products and vegetable-based diets. Oral branched-chain amino acids can be considered for individuals intolerant of all protein. iii. Lactulose. Dosing aims at two to three soft bowel movements per day. Antibiotics are reserved for patients who respond poorly to disaccharides or who do not exhibit diarrhea or acidification of the stool. Chronic antibiotic use (neomycin, metronidazole) requires careful renal, neurological, and/or otological monitoring. iv. Refer for liver transplantation in appropriate candidates. For problematic encephalopathy (nonresponsive to therapy), consider imaging of splanchnic vessels to identify large spontaneous portal-systemic shunts potentially amenable to radiological occlusion. In addition, consider the combination of lactulose and neomycin, addition of oral zinc, and invasive approaches, such as occlusion of TIPS or surgical shunts, if present. Minimal or Subclinical Encephalopathy Treatment can be instituted in selected cases. The most characteristic neuropsychological deficits in patients with cirrhosis are in motor and attentional skills (60). Although these may impact the ability to perform daily activities, many subjects can compensate for these defects. Recent studies suggest a small but significant impact of these abnormalities on patients' quality of life (61), including difficulties with sleep (62). In patients with significant deficits or complaints, a therapeutic program based on dietary manipulations and/or nonabsorbable disaccharides may be tried. Benzodiazepines should not be used for patients with sleep difficulties.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11467622     DOI: 10.1111/j.1572-0241.2001.03964.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  153 in total

1.  [6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974)].

Authors:  B Cinader
Journal:  Medicina (B Aires)       Date:  1975 Jul-Aug       Impact factor: 0.653

Review 2.  Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS--a review of clinical, biochemical, and electrophysiological data.

Authors:  S Mitzner; J Loock; P Peszynski; S Klammt; J Majcher-Peszynska; A Gramowski; J Stange; R Schmidt
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

3.  Relationship between encephalopathy and portal vein-vena cava shunt: value of computed tomography during arterial portography.

Authors:  Qian Chu; Zhen Li; Su-Ming Zhang; Dao-Yu Hu; Ming Xiao
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

Review 4.  Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.

Authors:  Bodil Als-Nielsen; Lise L Gluud; Christian Gluud
Journal:  BMJ       Date:  2004-03-30

5.  Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.

Authors:  C S Landis; M Ghabril; V Rustgi; A M Di Bisceglie; B Maliakkal; D C Rockey; J M Vierling; J Bajaj; R Rowell; M Santoro; A Enriquez; M Jurek; M Mokhtarani; D F Coakley; B F Scharschmidt
Journal:  Dig Dis Sci       Date:  2016-01-19       Impact factor: 3.199

Review 6.  Branched-chain amino acids for people with hepatic encephalopathy.

Authors:  Lise Lotte Gluud; Gitte Dam; Iñigo Les; Giulio Marchesini; Mette Borre; Niels Kristian Aagaard; Hendrik Vilstrup
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

7.  Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification.

Authors:  Paolo Fonio; Andrea Discalzi; Marco Calandri; Andrea Doriguzzi Breatta; Laura Bergamasco; Silvia Martini; Antonio Ottobrelli; Dorico Righi; Giovanni Gandini
Journal:  Radiol Med       Date:  2017-05-16       Impact factor: 3.469

Review 8.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

9.  Sleep disturbance and daytime sleepiness in patients with cirrhosis: a case control study.

Authors:  Barbara Mostacci; Monica Ferlisi; Alessandro Baldi Antognini; Claudia Sama; Cristina Morelli; Susanna Mondini; Fabio Cirignotta
Journal:  Neurol Sci       Date:  2008-09-20       Impact factor: 3.307

Review 10.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.